DDDD.L Share News (DDDD)

4D Pharma Buys Assets From Partner In Deal Worth Up To EUR6 Million (ALLISS)

4d Pharma Annual Loss Widens On Higher Research Spending

Good news, and some not-so-good news from 4D pharma

(ShareCast News) - 4D pharma brought some good news and some bad news to the market on Friday, over its trials of irritable bowel syndrome (IBS) treatment Blautix, and it paediatric Crohn's disease treatment Thetanix. The AIM-traded pharmaceutical company, with a focus on the development of live bio

4D Pharma Quality Concerns Delay Thetanix Dosing, Recruits For Blautic

4D Pharma expands research with Tuscana acquisition

(ShareCast News) - 4D Pharma expanded its research capabilities on Wednesday, acquiring university-based startup Tuscana Health Limited. The AIM traded pharmaceutical company, focused on the development of live biotherapeutics, said Tuscana - based at University College Cork - was founded to investi

4D Pharma Acquires University Start-Up Company Tucana Health (ALLISS)

4d Pharma Gets Good Early Results From Blautix Trials

4d Pharma Raises GBP30.0 Million For Business Development (ALLISS)

4D Pharma Finds Live Biotherapeutic For Breast, Lung Cancer Treatment

4D Pharma Gets Approval For Phase 1 Study Of Crohn's Disease Drug

4D Pharma Progresses Pipeline As It Swings To Loss In First Half

4D Pharma Commences Dosing In Irritable Bowel Syndrome Clinical Trial

FTSE 250 movers: Miners drag index down, Synthomer spikes higher

(ShareCast News) - The FTSE 250 index was by late on Tuesday afternoon giving up some of the gains made late the day before, as commodities-focused stocks were hit by China's devaluation and corporate news received mixed reviews. By 1540 BST the index was down 0.47% at 17,677.29 points, with Vedanta

4D Pharma Agrees EUR4.8 Million Collaboration With APC Microbiome

4D Pharma posts "exciting" development results from MicroRx

Pharmaceutical company 4D Pharma said it had made significant progress in its research efforts using its proprietary platform MicroRx. The Manchester-based outfit was able to identify candidates for the treatment of severe asthma, allergic asthma and rheumatoid arthritis. The group also identified